About: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published in The Lancet

Attributes	Values
rdf:type	Item
description	artículu científicu (ast) wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1994 (uk) article publié dans la revue scientifique The Lancet (fr) im Februar 1994 veröffentlichter wissenschaftlicher Artikel (de) scientific article published in The Lancet (en) ശാസ്ത്രപ്രബന്ധം (ml)
publication date	wds:Q54066813-6434B7C4-5CE8-4D14-8F13-DB33CE1A511F
publication date	1994-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q54066813-C4BEC2AF-5CEB-41A0-80B2-490C437E8B93
language of work or name	English
cites work	wds:Q54066813-00916903-89AB-487B-92DC-84CAA9DF70B5 wds:Q54066813-035D52C5-D83B-43BF-9EB0-E040A4DE71FB wds:Q54066813-0C34FD23-E20A-4F58-923A-06A8D1002900 wds:Q54066813-0EA0D85E-242A-45A0-B79E-AD32ECD426B4 wds:Q54066813-1E31DD3F-3A6C-47EE-8753-E1EA6F657391 wds:Q54066813-1F71D1AA-5BD8-4B51-B6B4-C3E890615749 wds:Q54066813-2A27AAE9-F938-42EF-9EAD-0C05286AD60E wds:Q54066813-304BF69E-0120-4108-BEC5-A109B0974AEE wds:Q54066813-3F66AF7C-4EC0-408C-83F6-E6BE27C40A34 wds:Q54066813-41EF2DCC-0AB5-48C1-A7D4-3957834C203C wds:Q54066813-45C91482-4CA8-48A0-BE13-E20C0E3172E7 wds:Q54066813-4733D50A-E1FF-4E3A-B1CD-A8FE34E0DAB6 wds:Q54066813-486C65A7-1DF2-4435-873A-C6472CEF38B9 wds:Q54066813-4B06112C-24EC-4E83-8738-1D6FB887C0DD wds:Q54066813-4DD6E9BC-2A2E-4E3B-B985-52A84C773813 wds:Q54066813-4EF6B713-C7ED-48BB-852F-1D02E998F9D0 wds:Q54066813-503567EB-6AC5-4076-B69F-BD273B886161 wds:Q54066813-544F1845-76C1-4DF5-94FF-A5CB2AC96ED6 wds:Q54066813-5A6E8BA3-2498-4988-9C53-A6AC1AA2E4D5 wds:Q54066813-5BFA62F7-A7BC-48A7-A491-2AEC09500E85 wds:Q54066813-5DC3C8E3-4552-407A-B3B0-56E290E355DB wds:Q54066813-68920CA4-779F-40C5-BDDB-DA62F9647196 wds:Q54066813-6B0119D7-60F0-4D73-9674-7CCADAFE2DFE wds:Q54066813-745BFD8D-B5DE-4CF0-BFF4-12E31D6A005B wds:Q54066813-87F3BEDA-3F9F-4226-9C29-16C544A318E0 wds:Q54066813-8BA6DB2A-F194-43EE-9305-E1EF89E6CF9B wds:Q54066813-937A2B40-B816-45BD-88C4-7CD4704E82AA wds:Q54066813-95C80513-BBC9-49CA-AA77-3A6F4608999D wds:Q54066813-A1A2B103-50FD-4097-B0FA-976AF36386FE wds:Q54066813-A2842042-EB50-4432-BD50-59686709A69A wds:Q54066813-A6F06A49-B485-4B12-A805-D84F62E2D697 wds:Q54066813-A7DC9821-6D8E-4DC9-84C4-7F05B0AB60B5 wds:Q54066813-AA14CC73-2D55-4B2C-B05B-AEF83A084344 wds:Q54066813-AD258D4D-59EB-48E5-90D7-D4557E230E1B wds:Q54066813-C161FAE9-F9ED-4FAE-8EBD-6BEDD4D10552 wds:Q54066813-C924BF6B-27E4-4140-B7A5-2501D73E539A wds:Q54066813-D4185C0F-2070-43E4-A996-3D4537F397FF wds:Q54066813-D782076D-F0CB-44AD-89E3-E98606B223BC wds:Q54066813-E1C34D27-A94B-460F-9079-2D3D5F6FFDAC wds:Q54066813-E6C92164-5462-48FC-A166-7AE465AF8B81 wds:Q54066813-F6EE4BB6-9EE7-407E-8F3F-748D8E3BAC35
cites work	Why do we need systematic overviews of randomized trials? Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Optimizing thrombolytic therapy of acute myocardial infarction Adoption of thrombolytic therapy in the management of acute myocardial infarction Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration Selection of patients with acute myocardial infarction for thrombolytic therapy An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction. Myocardial reperfusion: a double-edged sword? Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators Thrombolytic therapy for patients with myocardial infarction presenting after six hours Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Urochinasi per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study) Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical t Coronary thrombolysis for the elderly? Thrombolytic therapy for elderly patients How sound is the evidence that thrombolysis increases the risk of cardiac rupture? Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies Immediate angioplasty for acute myocardial infarction Reperfusion therapy in inferior myocardial infarction The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase Myocardial reperfusion: is it ever too late? Effect of intravenous streptokinase on early mortality in patients with suspected acute myocardial infarction. A meta-analysis by anatomic location of infarction . Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. The MITI Project Group Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] study group). Coronary angioplasty in acute myocardial infarction: should it be done? To whom? When? Patient selection for thrombolytic therapy
author name string	wds:Q54066813-953DB1CE-11DF-42CE-9B02-364A55EF8EB8
author name string	FIBRINOLYTICTHERAPYTRIALISTSF
rdfs:label	Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients (en) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients (nl)
skos:prefLabel	Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients (en) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software